News

The merger, in combination with an expansive capital investment program, will create product development and production capabilities across 600,000ft² of manufacturing space. The combined scale and breadth of

The agreement includes cell line optimization, analytical development and manufacturing scale-up activities for Omni Bio’s leading AAT Fc fusion protein with the goal of providing cGMP product to

ILUVIEN is Alimera’s sustained release intravitreal injection for the treatment of diabetic macular edema. As part of the deal, STA will also be responsible for managing all regulatory

The petition was made pursuant to Section 22A of the Medicines and Related Substances Act No. 101 of 1965, which provides for pharmaceutical research with cannabis. Apart from

The platform was selected after an extensive evaluation process carried out by members of the Quality Assurance and IT teams at Pierre. Initially, the QUMAS solution will be

As part of the deal, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the 4-Antibody Retrocyte Display platform, while Merck will

Rasagiline tablets, developed by Teva, are approved in more than 40 countries for the treatment of PD. Teva received its first approval in 2005 in Israel and Europe

The EC approval makes RoACTEMRA the first anti IL-6 receptor biologic available as subcutaneous and intravenous (IV) formulations for both monotherapy and combination therapy with methotrexate (MTX). The

Neumedicines’ proposal, ‘Recombinant Interleukin-12, a Broad-Spectrum Biologic for the Treatment of Battle and Traumatic Wound Infections’, was submitted in response to the Fiscal Year 2014 (FY14) Defense Medical